Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The user experienced reduced hair loss using grey-market KX-826 alongside Minoxidil foam, achieving better results with Minoxidil liquid but restricted to foam due to an allergy. Initial side effects included shortness of breath, racing heart, and dizziness, which subsided after the first week.

A new technique developed by scientists in Japan to reverse balding using hair follicle cell transplants, and the discussion around the effectiveness of this approach compared to other treatments such as Minoxidil, finasteride, RU58841, Replicel, and Hairclone.

The conversation is about hair loss treatments, specifically discussing the effectiveness of Red Ginseng Extract in promoting hair growth. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about a user starting a hair loss treatment with Dutasteride, Minoxidil, and RU58841, hoping to prevent baldness. Other users comment on the user's current hair condition and the intensity of the chosen treatment.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation suggests that changing diet and lifestyle has little to no effect on male pattern baldness (MPB), which is largely determined by genetics. Some individuals noted personal improvements in hair condition with healthier diets, but the consensus is that diet alone cannot prevent or reverse MPB.

The post is about a user's progress with using minoxidil and finasteride for hair loss. One user suggests that dermarolling may also be contributing to the positive results.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

There is concern about a potential ban on finasteride and dutasteride in the EU, with users discussing the impact on hair loss treatment. Some suggest alternative treatments or express skepticism about the likelihood of a ban.

Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

The conversation humorously discusses hair loss treatments, focusing on the use of finasteride and dutasteride, with some users debating the effectiveness and cost of different dosages. Some users mention using topical minoxidil and express concerns about side effects and availability of higher doses.

The user experienced increased hair density after 8 months of using dutasteride and 6 months of oral minoxidil. Some users joked about side effects, while others discussed the effectiveness of various treatments like finasteride and rosemary oil.

Oral minoxidil is claimed to be more effective and easier to use than topical minoxidil, with a 100% response rate, but it may cause unwanted body hair growth and has potential heart-related side effects. Topical minoxidil is less effective for many due to enzyme limitations, can cause scalp issues, and is more challenging to apply, but it avoids systemic side effects.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

A user is anxious about starting finasteride for hair loss despite believing in its effectiveness. Others suggest starting with a lower dose and emphasize the low risk of side effects.

A user ordered pyrilutamide (KX826) to stop hair loss and is seeking success stories. Replies indicate that it's too early to evaluate the product's effectiveness, as it takes several months to see results.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

User experienced hair loss after taking creatine with finasteride for 8 years. Others shared similar experiences, but some suggested it could be a minoxidil shed.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.